Allergan's website for eyelash thickener Latisse draws FDA warning
This article was originally published in Scrip
Executive Summary
The US FDA's division of drug marketing, advertising and communications (DDMAC) has issued a letter to Allergan less than a year after the US launch of its eyelash growth drug, Latisse (0.03% bimatoprost ophthalmic solution), charging that the company's consumer website in support of the product and other promotional materials were misleading. Latisse was introduced earlier this year after approval in December (scripnews.com, December 30th, 2008).